Compare QUIK & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QUIK | KALA |
|---|---|---|
| Founded | 1988 | 2009 |
| Country | United States | United States |
| Employees | 51 | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 211.8M | 172.0M |
| IPO Year | 1997 | 2017 |
| Metric | QUIK | KALA |
|---|---|---|
| Price | $18.39 | $2.71 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $11.00 | ★ $31.50 |
| AVG Volume (30 Days) | 716.1K | ★ 2.9M |
| Earning Date | 05-12-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 67.39 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $20,112,000.00 | N/A |
| Revenue This Year | $75.17 | N/A |
| Revenue Next Year | $16.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.80 | $0.07 |
| 52 Week High | $22.69 | $20.58 |
| Indicator | QUIK | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 57.95 | 71.54 |
| Support Level | $5.83 | $0.32 |
| Resistance Level | N/A | $3.96 |
| Average True Range (ATR) | 2.06 | 0.23 |
| MACD | -0.01 | 0.29 |
| Stochastic Oscillator | 53.05 | 68.19 |
QuickLogic Corp is a fabless semiconductor company developing programmable logic semiconductor technologies, including embedded Field Programmable Gate Array (eFPGA) intellectual property (IP) and specialized FPGA devices. Its product offerings include the eFPGA IP licensing business and associated professional services, as well as a range of FPGA silicon products, including EOS, ArcticLink III, PolarPro 3, PolarPro II, PolarPro, and Eclipse II products, among others. The company's customers come from various markets, including aerospace and defense, industrial and infrastructure systems, data processing and computing platforms, and certain embedded and edge computing applications. Geographically, it generates maximum revenue from North America and the rest from Asia Pacific and Europe.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.